Septerna

SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

biotech lab

Analyst Color

Biotech

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

RHHBY

SEPN

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

Analysts

Upgrades

Pre-Market Outlook

Markets

This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Prague,,Czech,Republic,-,March,31:,Hilton,Hotels,And,Resorts

MNPR

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Septerna Inc

Legal

Press Releases

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Septerna to Present at TD Cowen 45th Annual Health Care Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Earnings

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Septerna to Present at Jefferies Global Healthcare Conference

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

Maze Therapeutics

MBX Biosciences

Nektar Therapeutics

Nuvation Bio

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tilray Brands

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

HC Wainwright & Co.

Cantor Fitzgerald

Wells Fargo

JP Morgan

Comments

Septerna

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell